ITOG Leadership

Executive Committee
Manisha H. Shah, MD, Chair
The Ohio State University
Sareh Farangi, MD, Secretary
Harvard Medical School
David Pfister, MD,
Chair, Protocol Committee
Memorial Sloan-Kettering Cancer Center
Eric Sherman, MD,
Co-Chair Protocol Committee
Memorial Sloan-Kettering Cancer Center
Dwight Vicks III MBA Treasurer
President, Vicks, Inc.
Lori Wirth, Immediate Past Chairperson
Massachusetts General Hospital

Board of Directors
Keith C. Bible, M.D., Ph.D.
Mayo Clinic (Rochester)
Naifa Busaidy, MD
MD Anderson Cancer Center
Maria Cabanillas, MD
MD Anderson Cancer Center
James Fagin, MD
Memorial Sloan-Kettering
Andrew Gianoukakis, MD
University of California, Los Angeles
Elizabeth Grubbs, MD
MD Anderson Cancer Center
Bryan Haugen, MD
University of Colorado, Health Sciences Center
Alan Ho MD, PhD
Memorial Sloan-Kettering
Gregory Randolph,
MD Massachusetts Eye and Ear Infirmary
Bruce G. Robinson,
MD University of Sydney
Julie Ann Sosa, M.D.
University of California, San Francisco

ITOG Chair Quarterly Update Newsletter
April 2019

Manisha Shah, MD
Dear ITOG Friends!

Happy Spring 2019! Hope that this season brings you lots of positive energy and enthusiasm that feeds your soul and your passion! I look forward to seeing everyone later this week at the 2019 Annual ITOG Meeting in NYC and will miss those who are unable to attend. Many thanks to Drs. David Pfister, Eric Sherman and the rest of the team at MSKCC and Yaniv Hourvas from Weill Cornell Medical College for planning excellent meeting with ‘one of a kind’ agenda for entire meeting that will mainly focus on Thyroid Cancer.!

Since our first quarterly newsletter in Jan 2019, we have several updates at ITOG that I am delighted to share with you as top news items below. I look forward to having a dialogue with you while I share ITOG's progress this past year and new initiatives at the Business Meeting on Saturday, May 4th in NYC.

On a personal level, I wanted to give you heads up about my bald head that is in solidarity with my family member diagnosed with Hodgkin’s lymphoma in mid-March 2019. I am stronger being able to take cancer journey with her and we are aiming for a cure! Such personal experiences fuel my duty at ITOG to do my best to catalyze cure for thyroid cancer working with all of you! ITOG is so lucky to be able to count on each and every one of us so let’s go!

www.ITOG.org

ITOG Active Clinical Trials

ACCRU/ITOG 1504 Combination Immunotherapy with Multikinase Inhibitor (MKI) in Progressive, Radiodine-resistant Differentiated Thyroid Cancers
Accrual Status: Accruing
Accrual Goal: 60
Current Accrual: 46 (Cohort 1 - 30 Cohort 2 - 16)
Sponsors: Eisai/Merck
Coordinating organization: ACCRU
Principal Investigator (PI): Bryan Haugen, MD at University of Colorado Medical Center
Principal Investigator Email: Bryan.Haugen@ucdenver.edu
Co-PI: Lori Wirth, MD
Publication/Presentation Status: Pending

***Status Change March 26, 2019 - Cohort 1 is permanently closed to patient accrual per protocol as of March 26, 2019.

Selumetinib plus RAI for RAI-Avid Thyroid Cancers
Accrual Status: Accruing
Accrual Goal: 60
Current Accrual: 51
Sponsor: AstraZeneca
Coordinating organization: ACCRU
Principal Investigator: Alan Ho, MD at Memorial Sloan-Kettering Cancer Center
Principal Investigator Email: hoa@mskcc.org
Co-PI: Mabel Ryder, MD
Publication/Presentation Status: Pending

---------------------------------------------
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)  
Accrual Status: Accruing  
Sponsor: Loxo-Oncology  
Coordinating organization: LOXO-Oncology  
Leader at ITOG: Lori Wirth and ITOG protocol-specific steering committee  
Leader Email: Lwirth@mgh.harvard.edu  
Publication Status: Pending  
Presentations: ASCO Jun 2018, ATA Oct 2018

Phase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy  
Accrual Status: Permanently closed  
Accrual Goal: 25  
Current Accrual: 25  
Sponsors: CTEP/NCI, ITOG  
Coordinating organization: ACCRU  
Principal Investigator: Manisha Shah, MD at The Ohio State University  
Principal Investigator Email: manisha.shah@osumc.edu  
Co-PI: Maria Cabanillas, MD  
Publication Status: Published Journal of Clinical Oncology - Oct 2017 JCO.2017.73.0226  

An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)  
Accrual Status: Terminated  
Sponsor: Eisai  
Coordinating organization: Eisai  
Leader at ITOG: Lori Wirth and ITOG protocol-specific steering committee  
Leader Email: LWIRTH@mgh.harvard.edu  
Publication/Presentation Status: Pending

ALLIANCE A091302  
Randomized Phase II Study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer (PI- Dr. E. Sherman); Alliance study, but with disappointing accrual. Collaboration with ITOG with acknowledgement based on criteria of accrual at ITOG centers. Currently 26 patients accrued; target is 30-34 patients. University of Michigan and Ohio State have already opened the study. Mass General and Fox Chase Cancer Center are about to open.  
Target Accrual goal: 30  
Accrued to date: 30  
Principal Investigator: Eric Sherman, MD Memorial-Sloan Kettering Cancer Center  
Principal Investigator Email: shermane@mskcc.org

ITOG Upcoming Trials

CTEP approved LOI #10240: Phase II Study of Cabozantinib in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after 1 Prior VEGFR-Targeted Therapy  
(Protocol in Development)  
Principal Investigator: Bhavana Konda, MD  
Principle Investigator Email: Bhavana.Konda@osumc.edu  
The Ohio State University

OSU 17277: A Phase 1 Trial of concurrent Intensity Modulated Radiation Therapy (IMRT) and DABRAFENIB/TRAMETINIB IN BRAF MUTATED ANAPLASTIC OR POORLY DIFFERENTIATED THYROID CANCER  
(In Development)
ITOG TOP NEWS!

The 2019 ITOG Annual Meeting is around the corner!!
Friday May 3 - Sunday May 5, 2019
Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center Auditorium
417 E. 68th St, New York, NY 10065
Many thanks to ITOG members at the MSKCC and Weill Cornell for hosting this meeting. For any questions, please contact Afia Sultana or David Pfister by email, or call 646-888-4237.

**Registrations as of 4/22/19 - 78

Click here to Register

Nearby Accommodations

The Helmsley Medical Tower 1320 York Ave between E.70 and 71st St, New York, NY 10021
The Helmsley Medical Tower Reservations (212) 472-8400
Gardens Suites Hotel by Affinia 215 E 64th St, New York, NY 10065
Gardens Suites Hotel Reservations (212) 355-1230
Loews Regency New York 540 Park Ave, New York, NY 10065
Loews Regency Reservations (212) 759-4100
Renaissance New York Hotel 57130 E 57th St, New York, NY 10022
Renaissance New York Hotel 57 Reservations (212) 753-8841

Thank you David G. Pfister M.D. and the MSKCC 2019 ITOG Annual Meeting Host Committee Eric Sherman, Alan Ho, Michael Tuttle, Yariv Houvras!

We are looking forward to the New Agenda Format in which the Protocol Committee Task Force Leaders Committee had greater responsibility for speaker selection and planning the panels.

Bryan R. Haugen M.D., Endocrinology
University of Colorado Health Sciences Center
Congratulations to Dr. Haugen and participating sites on achieving Accrual Goal of 30 Cohort 1, in ACCRU/ITOG 1504 Clinical Trial.
Participating Sites below
Robert F. Gagel, M.D. Endocrinology  
MD Anderson Cancer Center  
Lifetime Achievement Award,  
MEN International Workshop  
Houston, TX March 27, 2019  
Pictured L-R, Andrew (son), Beth (daughter),  
Margo (wife), Robert (Bob) Gagel

Kenneth D. Burman M.D. Endocrinology  
Washington Hospital Center  
Outstanding Educator Award  
Endocrine Society, January 2019

Dr. Burman is an extraordinary clinician and teacher who has contributed significantly to the Endocrine Society missions of education and science.

Matthew Ringel M.D. Endocrinology  
Ohio State University  
Elected to membership in the  
Association of American Physicians (AAP)  
Dr. Ringel was selected based on his seminal discoveries that have significantly contributed to our understanding of the molecular pathogenesis of thyroid cancer.

ITOG/REACT Merger Update  
The merger of REACT and ITOG was unanimously approved by ITOG members and successfully
completed at the end of December 2018. We are most grateful to Michelle LeBeau's mother Donna, and sister Kimberly Caplea, for choosing ITOG to carry on Michelle's legacy. In Donna's words, "ITOG is the preeminent organization that brings together the leaders in the field to develop better treatments for all types of thyroid cancer, including MTC."

Donna LeBeau and Kimberly Caplea will be attending the 2019 ITOG Annual Meeting when ITOG members will convey their appreciation for joining forces.

There is still time to submit your request!
Call for ITOG Committee Members
Terms May 2019 – April 2022
Click Here to Volunteer for ITOG Committees
> Basic Science and Correlative Science
> Clinical Protocols
> Finance
> Website and Communications
> Annual Meeting Planning Task Force

Call for Hosting 2021 ITOG Annual Meeting
Call for 2021 Annual Meeting Host Now Open
Click here to Volunteer to Host the 2021 ITOG Annual Meeting
Or email the Chair at Manisha.shah@osumc.edu or judy.dallas@osumc.edu

Member Feedback

Thyroid Cancer News

Lilly Announces Agreement To Acquire Loxo Oncology

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines through the addition of a marketed therapy and a pipeline of highly selective potential medicines for patients with genomically defined cancers. Loxo Oncology's pipeline includes LOXO-292, an oral RET inhibitor being studied across multiple tumor types, which recently was granted Breakthrough Therapy designation by the FDA and could launch in 2020.

2019 National and International Meetings And Events

- ITOG Annual Meeting May 3-5, New York, NY
- Alliance 2019 Spring Group Meeting May 9 – 11, 2019, Rosemont, IL
- BIT's 12th Annual World Cancer Congress 2019 May 15-17, Osaka, Japan
- ASCO 2019 May 21 – June 4, Chicago, IL
- World Congress on Thyroid Cancer 3.5, June 20 – 22, Rome, Italy
Development

Donations to ITOG support our mission to catalyze a cure for thyroid cancer. Thyroid cancer has been relatively underfunded compared to other solid tumors. ITOG and its members have played a critical role in organizing the most sophisticated clinical trials to discover and characterize new drugs for thyroid cancer treatment. Your support will make a difference. Philanthropy is a key for ITOG to achieve success. Hundreds of individuals whose lives have been touched by thyroid cancer have contributed to our mission. Make your voice heard by donating today.

ITOG is a 501(c)(3) tax-exempt public charity. Donations are tax deductible.
Get Involved

Submit an Item to the ITOG Monthly Update

All submissions must be relevant to the mission and Purpose of ITOG. Please take time to proof and edit submissions. Requesting Member submissions no later than February 28, 2019

Please keep in mind we may not use all submissions, but appreciate you sharing. We reserve the right to edit submissions for content and length. Please send to judy.dallas@osumc.edu

Submission Guidelines:

- No more than 150 words
- Include the name of author, job title, email and institution
- All submissions should be saved in MS Word
- Photos and artwork send as .jpg files.
- Recent publications
- Upcoming & recently completed presentations (within 90 days)
  - Organization, Date, Location, Title
- Open Positions for Employment in Your Division/Department
  - Position title, location, contact information

Copyright © 2019 *International Thyroid Oncology Group (ITOG)*, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.